{"Clinical Trial ID": "NCT00304096", "Intervention": ["INTERVENTION 1:", "Strategy 1: Hormonal treatment received", "Participants received hormonal therapy", "INTERVENTION 2:", "Stratum 2: Had not received hormonal therapy", "The participants had not received hormonal treatment."], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "Adenocarcinoma of the breast confirmed histologically or cytologically", "Stage III or IV disease rate", "Primary or recurrent diseases", "Invasive Lobular Carcinoma Permitted", "HLA-A1, -A2, -A3, or -A31 positive", "Underwent and recovered from previous primary treatment", "Patients who do not have clinical or radiological evidence of a disease that has already had a diagnosis of Stage III or IV breast cancer must have undergone prior anti-neoplastic therapy including, but not limited to, surgery, chemotherapy and radiation therapy in the past 36 months.", "\u2022 Must have at least one pelvis of undissected axillary and/or inguinal lymph nodes", "No history of brain metastases", "Status of the hormone receptor", "A positive or negative estrogen tumour", "CHARACTERISTICS OF PATIENTS:", "ECOG performance status of 0 or 1", "Weight > 110 lbs (without clothing)", "Men or women", "\u2022 Menopausal status not specified", "Absolute number of neutrophils > 1000/mm^3", "Number of platelets > 100 000/mm^3", "Hemoglobin > 9 g/dL", "Hemoglobin A1c < 7%", "ASAT and ALT 2.5 x upper limit of normal (ULN)", "Bilirubine 2.5 x ULN", "2.5 x ULN alkaline phosphatase", "Creatinine 1.5 x ULN", "Negative to HIV", "- Hepatitis C negative", "No pregnancy or breast-feeding", "Negative pregnancy test", "Fertile patients should use effective contraception", "No known or suspected allergy to any component of the vaccine", "No active infection requiring antibiotics", "No Class III or IV heart disease from the New York Heart Association", "No autoimmune disorder requiring cytotoxic or immunosuppressive treatment or autoimmune disorder with visceral impairment, except as follows:", "Laboratory evidence of autoimmune disease (e.g. ANA positive) without symptoms", "Clinical evidence of vitiligo", "Other forms of depigmentation", "Mild hyperarthritis requiring nonsteroidal anti-inflammatory drugs", "No medical contraindications or potential problems that would prevent participation in the study", "THERAPE PRIOR CONCURENT:", "More than 4 weeks since previous surgery", "More than 4 weeks since simultaneous chemotherapy and radiotherapy", "More than 4 weeks since previous desensitisation injections and no concomitant allergy", "More than 4 weeks from previous parenteral, oral or inhaled corticosteroids", "No concomitant inhaled steroid (e.g. Advair\u00ae or triamcinolone acetonide)", "Previous topical corticosteroids or authorized co-occurring corticosteroids", "More than 4 weeks from the beginning and no competing growth factors (e.g. epoetin alfa, darbepoetin alfa or pegfilgrastim)", "More than 4 weeks from the beginning and no other concomitant experimental drugs", "More than 4 weeks since the previous one and no other agents associated with putative immunomodulatory activity, with the exception of nonsteroidal anti-inflammatory agents", "A prior and concomitant hormonal treatment (e.g. tamoxifen, raloxifene, toremifene, flulvestrant, letrozole, anastrozole or exemestane) is permitted.", "No prior vaccination with synthetic peptides in this protocol", "\u2022 Vaccines against infectious diseases (e.g. influenza) are allowed, provided they are given 2 weeks before or 2 weeks after the vaccine is studied.", "\u2022 Short-term treatment for acute conditions not related to breast cancer is allowed", "No concomitant illicit drugs"], "Results": ["Performance measures:", "The number of participants who experienced dose-limiting adverse events", "The safety of the 9 peptide mixture if less than 33% of patients have dose-limiting toxicity", "Time limit: 30 days after administration of the last vaccine", "Results 1:", "Title of the arm/group: Strata 1: Hormonal therapy received", "Description of the arm/group: Participants received hormonal therapy", "Total number of participants analysed: 6", "Type of measurement: Number", "Unit of measurement: participants 1", "Results 2:", "Title of the arm/group: Stratum 2: Had not received hormonal therapy", "Description of the arm/group: Participants had not received hormonal treatment", "Total number of participants analysed: 5", "Type of measurement: Number", "Unit of measurement: participants 0"], "Adverse Events": ["Undesirable Events 1:", "Total: 1/6 (16.67%)", "Fever [1]1/6 (16.67%)", "Adverse Events 2:", "Total: 0/5 (0.00 per cent)", "Fever [1]0/5 (0.00 %)"]}